NewcelX AG

NCEL · NASDAQ

$2.61−$0.02 (−0.76%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.63

About NCEL

NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.

Employees: 1
Headquarters: Zurich, Zuerich
Listed: Jan 29, 2021
Sector: Health Care
Industry: Biotechnology
Website: nlspharma.com

Leadership

NewcelX AG executives
Name	Title	Since	Age
Ronald Hafner	—	—	61
Alexander Zwyer	—	2015	56
Nicole Fernandez-mcgovern	—	—	52
Eric Konofal	—	—	57
Florence Aknin	—	—	58
Gian-Marco Rinaldi	—	—	57
Olivier Samuel	—	—	50
Cindy Rizzo	—	2020	—

Similar companies

Companies in the same industry as NewcelX AG

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.